{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:20:46Z","timestamp":1760782846721},"reference-count":94,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.ejca.2005.11.035","type":"journal-article","created":{"date-parts":[[2006,6,23]],"date-time":"2006-06-23T14:12:04Z","timestamp":1151071924000},"page":"1554-1563","source":"Crossref","is-referenced-by-count":28,"title":["Myeloma bone disease and treatment options"],"prefix":"10.1016","volume":"42","author":[{"given":"Howard S.","family":"Yeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2005.11.035_bib1","first-page":"291","article-title":"Bone destruction and hypercalcemia in plasma cell myeloma","volume":"13","author":"Mundy","year":"1986","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.ejca.2005.11.035_bib2","first-page":"29","article-title":"Multiple myeloma, review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2005.11.035_bib3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.035_bib4","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1056\/NEJM197512252932602","article-title":"Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo","volume":"293","author":"Kyle","year":"1975","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2005.11.035_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejca.2005.11.035_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1084\/jem.188.5.997","article-title":"TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts","volume":"188","author":"Fuller","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2005.11.035_bib7","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.4049\/jimmunol.138.5.1464","article-title":"Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption","volume":"138","author":"Stashenko","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2005.11.035_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/8756-3282(91)90057-P","article-title":"Mechanisms of osteolytic bone destruction","volume":"12","author":"Mundy","year":"1991","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.ejca.2005.11.035_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.ejca.2005.11.035_bib10","doi-asserted-by":"crossref","unstructured":"Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11581-6. Epub 2001 Sep 18.","DOI":"10.1073\/pnas.201394498"},{"issue":"13","key":"10.1016\/j.ejca.2005.11.035_bib11","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2005.11.035_bib12","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib13","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2005.11.035_bib14","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2005.11.035_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0889-8588(18)30345-9","article-title":"Mechanisms of bone lesions in multiple myeloma","volume":"6","author":"Bataille","year":"1992","journal-title":"Hematol Oncol Clin North Am."},{"issue":"8","key":"10.1016\/j.ejca.2005.11.035_bib16","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood.V86.8.3151.3151","article-title":"Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin","volume":"86","author":"Barille","year":"1995","journal-title":"Blood."},{"key":"10.1016\/j.ejca.2005.11.035_bib17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2005.11.035_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V74.1.380.380","article-title":"Production of interleukin-1 by bone marrow myeloma cells","volume":"74","author":"Cozzolino","year":"1989","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2005.11.035_bib19","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.V73.8.2145.2145","article-title":"Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma","volume":"73","author":"Kawano","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V93.1.300","article-title":"Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"93","author":"Lacy","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJM198708273170902","article-title":"Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells","volume":"317","author":"Garrett","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.035_bib22","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood.V94.11.3883","article-title":"Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma-associated osteolytic bone disease","volume":"94","author":"Hjertner","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib24","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V88.10.3998.bloodjournal88103998","article-title":"Hepatocyte growth factor and its receptor c-met in multiple myeloma","volume":"88","author":"Borset","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ajh.2830450115","article-title":"Production of parathyroid hormone-related protein by cultured human myeloma cells","volume":"45","author":"Suzuki","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2005.11.035_bib26","first-page":"29","article-title":"Multiple myeloma, review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clin Proc"},{"issue":"P","key":"10.1016\/j.ejca.2005.11.035_bib27","first-page":"138","article-title":"Analysis of compression fractures in patients with newly diagnosed multiple myeloma on comprehensive therapy (abstr)","volume":"221","author":"Angtuaco","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2005.11.035_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1148\/radiology.193.2.7972760","article-title":"Multiple myeloma: MR patterns of response to treatment","volume":"193","author":"Moulopoulos","year":"1994","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2005.11.035_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1148\/radiology.204.1.9205247","article-title":"Vertebral compression fractures in multiple myeloma. II. Assessment of fracture risk with MR imaging of spinal bone marrow","volume":"204","author":"Lecouvet","year":"1997","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2005.11.035_bib30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.035_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1148\/radiology.204.1.9205246","article-title":"Vertebral compression fractures in multiple myeloma. I. Distribution and appearance at MR imaging","volume":"204","author":"Lecouvet","year":"1997","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ejca.2005.11.035_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.ejca.2005.11.035_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.ejca.2005.11.035_bib34","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib35","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/0360-3016(88)90232-5","article-title":"Radiotherapy in the treatment of multiple myeloma","volume":"15","author":"Bosch","year":"1988","journal-title":"Int J Rad Onc Biol Phys"},{"key":"10.1016\/j.ejca.2005.11.035_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-8140(91)90144-6","article-title":"Palliative radiotherapy in plasma cell myeloma","volume":"20","author":"Adamietz","year":"1991","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.ejca.2005.11.035_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hon.2900060221","article-title":"A review of the place of radiotherapy in myeloma with emphasis on whole body irradiation","volume":"6","author":"Rostom","year":"1988","journal-title":"Hematological Oncology"},{"key":"10.1016\/j.ejca.2005.11.035_bib38","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/0959-8049(92)90527-9","article-title":"Prospective randomised study of double hemibody irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma","volume":"28A","author":"Giles","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2005.11.035_bib39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1365-2141.1997.d01-2108.x","article-title":"Long-term effects of localized spinal radiation therapy on vertebral fractures and focal lesions appearance in patients with multiple myeloma","volume":"96","author":"Lecouvet","year":"1997","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.ejca.2005.11.035_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0360-3016(97)00558-0","article-title":"Multiple myeloma of an extremity: Must the entire bone be treated","volume":"40","author":"Catell","year":"1998","journal-title":"Int J Radiation Oncology Biol Phys"},{"key":"10.1016\/j.ejca.2005.11.035_bib41","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood-2002-10-3250","article-title":"166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1\/2 trials","volume":"102","author":"Giralt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.leu.2403575","article-title":"A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma","volume":"19","author":"Dispenzieri","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.11.035_bib43","doi-asserted-by":"crossref","unstructured":"Iuliano F, Molica S, Abruzzese E, Peta A, Toraldo A, Palermo S. Samarium-153 Sm-EDTMP and zoledronic acid present synergistic action and are able to control pain and significantly improve QOL in elderly patients with multiple myeloma. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post Meeting Edition) (July 15 Suppl.), 2004: Abstract 6737.","DOI":"10.1200\/jco.2004.22.90140.6737"},{"issue":"7","key":"10.1016\/j.ejca.2005.11.035_bib44","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.exphem.2005.04.005","article-title":"PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis","volume":"33","author":"Goel","year":"2005","journal-title":"Exp Hematol."},{"issue":"2 Pt 1","key":"10.1016\/j.ejca.2005.11.035_bib45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/1078-0432.743.11.2","article-title":"Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment","volume":"11","author":"Ansiaux","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2005.11.035_bib46","first-page":"205","article-title":"Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor","volume":"22","author":"Monzen","year":"2004","journal-title":"Radiat Med."},{"issue":"249","key":"10.1016\/j.ejca.2005.11.035_bib47","first-page":"256","article-title":"Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures","author":"Mirels","year":"1989","journal-title":"Clin Orthop Relat Res"},{"issue":"suppl 12","key":"10.1016\/j.ejca.2005.11.035_bib48","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W","article-title":"Complications of bone metastases\u2014surgical management","volume":"88","author":"Healey","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.11.035_bib49","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/00007632-200210010-00019","article-title":"Point of view: An in vivo comparison of the potential for extravertebral cement leak after vertebroplasty and kyphoplasty","volume":"27","author":"Barr","year":"2002","journal-title":"Spine"},{"key":"10.1016\/j.ejca.2005.11.035_bib50","first-page":"1897","article-title":"Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: Technical aspects","volume":"18","author":"Jensen","year":"1997","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.ejca.2005.11.035_bib51","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/00007632-200107150-00026","article-title":"Initial outcome and efficacy of \u201ckyphoplasty\u201d in the treatment of painful osteoporotic vertebral compression fractures","volume":"26","author":"Lieberman","year":"2001","journal-title":"Spine"},{"issue":"415 Suppl","key":"10.1016\/j.ejca.2005.11.035_bib52","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1097\/01.blo.0000093841.72468.a8","article-title":"Vertebroplasty and kyphoplasty for osteolytic vertebral collapse","author":"Lieberman","year":"2003","journal-title":"Clin Orthop"},{"key":"10.1016\/j.ejca.2005.11.035_bib53","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeny","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.035_bib54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ddr.10071","article-title":"Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption","volume":"55","author":"Green","year":"2002","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.ejca.2005.11.035_bib55","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2005.11.035_bib56","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000218633","article-title":"Prospective randomized trial of dicholoromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study","volume":"18","author":"Heim","year":"1995","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2005.11.035_bib57","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"101","author":"McCloskey","year":"1998","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.ejca.2005.11.035_bib58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial","volume":"101","author":"Brincker","year":"1998","journal-title":"Brit J of Haematol"},{"key":"10.1016\/j.ejca.2005.11.035_bib59","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0140-6736(90)90452-B","article-title":"Use of pamidronate for multiple myeloma osteolytic lesions","volume":"335","author":"Man","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2005.11.035_bib60","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bjc.1994.344","article-title":"High-dose intravenous pamidronate for metastatic bone pain","volume":"70","author":"Purohit","year":"1994","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ejca.2005.11.035_bib61","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J of Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.035_bib62","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing the skeletal events in patients with advanced multilpe myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.035_bib63","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in pateints with advanced mutliple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.035_bib64","first-page":"575a","article-title":"Double blind-placebo controlled trial of intravenous ibandronate in breast cancer metastatic to bone","volume":"35","author":"Body","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.035_bib65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2019446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2005.11.035_bib66","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q","article-title":"A phase I open label, dose ranging trial of intravenous bolus zolderonic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.11.035_bib67","first-page":"478","article-title":"A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of metastatic bone disease","volume":"7","author":"Berenson","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2005.11.035_bib68","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.11.035_bib69","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.ejca.2005.11.035_bib70","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.11.035_bib71","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disocium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.11.035_bib72","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Letters to the Editor: Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.11.035_bib73","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"23","key":"10.1016\/j.ejca.2005.11.035_bib74","first-page":"5294","article-title":"The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway","volume":"58","author":"Shipman","year":"1998","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejca.2005.11.035_bib75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0145-2126(00)00087-4","article-title":"A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells","volume":"25","author":"Takahashi","year":"2001","journal-title":"Leuk Res."},{"key":"10.1016\/j.ejca.2005.11.035_bib76","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y","article-title":"Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma","volume":"55","author":"Radl","year":"1985","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2005.11.035_bib77","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.21104","article-title":"Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect","volume":"104","author":"Corso","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2005.11.035_bib78","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","article-title":"In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates","volume":"12","author":"Aparicio","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.11.035_bib79","first-page":"105a","article-title":"Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients","volume":"88","author":"Savage","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib80","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2005.11.035_bib81","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2005.11.035_bib82","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2401770","article-title":"Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines","volume":"14","author":"Tassone","year":"2000","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ejca.2005.11.035_bib83","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/10428190500221223","article-title":"Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro","volume":"46","author":"Ochiai","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.ejca.2005.11.035_bib84","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1532\/IJH97.05049","article-title":"Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma","volume":"82","author":"Ochiai","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejca.2005.11.035_bib85","first-page":"775a","article-title":"A single subcutaneous dose of an osteoprotegerin (OPG) construct (AMGN-0007) causes a profound and sustained decrease in bone resorption comparable to standard intavenous bisphosphonate in patients with multiple myeloma","volume":"98","author":"Greipp","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib86","first-page":"912","article-title":"Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells","volume":"63","author":"Shipman","year":"2003","journal-title":"Cancer Res"},{"issue":"3 Suppl","key":"10.1016\/j.ejca.2005.11.035_bib87","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.11134","article-title":"RANK-Fc: A therapeutic antagonist for RANK-L in myeloma","volume":"97","author":"Sordillo","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2005.11.035_bib88","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.11.035_bib89","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1158\/1078-0432.429.11.2","article-title":"Geranylgeranylated proteins are involved in the regulation of myeloma cell growth","volume":"11","author":"de Donk","year":"2005","journal-title":"Clin Can Res"},{"issue":"2","key":"10.1016\/j.ejca.2005.11.035_bib90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1099-1611(200003\/04)9:2<127::AID-PON438>3.0.CO;2-L","article-title":"Physical exercise and quality of life in cancer patients following high dose chemotherapy and autologous bone marrow transplantation","volume":"9","author":"Courneya","year":"2000","journal-title":"Psychooncology"},{"key":"10.1016\/j.ejca.2005.11.035_bib91","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.ejca.2005.11.035_bib92","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2005.11.035_bib93","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2019446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2005.11.035_bib94","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology Clinical Practice Guidelines: The role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906003200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906003200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T20:32:56Z","timestamp":1683491576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804906003200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":94,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0959804906003200"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2005.11.035","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}